There is a lot, and I mean a lot, of discussion right now about the potential for artificial intelligence (AI) to transform the pharmaceutical industry (as, indeed, there is across all industries).

Using artificial intelligence-powered software for screening electrocardiograms (ECGs) could deliver results more quickly and allow treatment to be started earlier, according to a new study.

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

There’s a tendency to overlook the fact that human health and animal health are closely intertwined. As an Ethnozoology published paper put it, “we share hundreds of diseases with animals, and ...

To encourage the uptake of complex therapies in clinical practice, brand teams must ensure they use data-driven insights to understand the needs and preferences of healthcare professionals (HCPs ...

April was both National Minority Health Month and Counselling Awareness Month, designations that call attention to persistent health disparities among racial and ethnic minorities and lift up the ...

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...

Pharmaceutical companies are eagerly pursuing GenAI products and use cases to generate value within their organisations. Many are heavily investing in consultants to help develop strategies and ...

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myeloma, but new data from the ...